Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

CRISPR-engineered T cells in patients with refractory cancer.

Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH.

Science. 2020 Feb 6. pii: eaba7365. doi: 10.1126/science.aba7365. [Epub ahead of print]

PMID:
32029687
2.

Place of Academic GMP Facilities in Modern Cell Therapy.

Bersenev A, Fesnak A.

Methods Mol Biol. 2020;2097:329-339. doi: 10.1007/978-1-0716-0203-4_21.

PMID:
31776936
3.

A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies.

Wang K, Liu Y, Li J, Wang B, Bishop R, White C, Das A, Levine AD, Ho L, Levine BL, Fesnak AD.

Cytotherapy. 2019 Oct;21(10):1081-1093. doi: 10.1016/j.jcyt.2019.07.002. Epub 2019 Aug 21.

PMID:
31445816
4.

Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy.

Fesnak AD, Hanley PJ, Levine BL.

Curr Hematol Malig Rep. 2017 Aug;12(4):335-343. doi: 10.1007/s11899-017-0395-9. Review.

5.

Showcasing Clinical Development and Production of Cellular Therapies.

Levine BL, Fesnak AD, Riviere I.

Mol Ther. 2017 Apr 5;25(4):827-828. doi: 10.1016/j.ymthe.2017.03.007. Epub 2017 Mar 22. No abstract available.

6.

Engineered T cells: the promise and challenges of cancer immunotherapy.

Fesnak AD, June CH, Levine BL.

Nat Rev Cancer. 2016 Aug 23;16(9):566-81. doi: 10.1038/nrc.2016.97. Review.

7.

CAR-T Cell Therapies From the Transfusion Medicine Perspective.

Fesnak A, Lin C, Siegel DL, Maus MV.

Transfus Med Rev. 2016 Jul;30(3):139-45. doi: 10.1016/j.tmrv.2016.03.001. Epub 2016 Mar 28. Review.

8.

NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.

Karimi MA, Bryson JL, Richman LP, Fesnak AD, Leichner TM, Satake A, Vonderheide RH, Raulet DH, Reshef R, Kambayashi T.

Blood. 2015 Jun 4;125(23):3655-63. doi: 10.1182/blood-2015-02-629006. Epub 2015 Mar 18.

9.

Conceptualizing physician professionalism.

Fesnak A, Rajput V.

JAMA. 2011 Apr 13;305(14):1412; author reply 1412-3. doi: 10.1001/jama.2011.425. No abstract available.

PMID:
21486972
10.

Violations of the 12/23 rule at the mouse immunoglobulin kappa locus, including V kappa-V kappa rearrangement.

Vinocur JM, Fesnak AD, Liu Y, Charan D, Prak ET.

Mol Immunol. 2009 Jul;46(11-12):2183-9. doi: 10.1016/j.molimm.2009.04.021. Epub 2009 May 20.

Supplemental Content

Loading ...
Support Center